Stocks and Investing
Stocks and Investing
Tue, November 23, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 22, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tiago Fauth Maintained (BMRN) at Buy with Increased Target to $105 on, Nov 22nd, 2021
Tiago Fauth of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $100 to $105 on, Nov 22nd, 2021.
Tiago has made no other calls on BMRN in the last 4 months.
There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 1 agrees with Tiago's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kennen MacKay of "RBC Capital" Maintained at Hold with Increased Target to $88 on, Thursday, July 29th, 2021
This is the rating of the analyst that currently disagrees with Tiago
- Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $96 on, Thursday, September 9th, 2021
Contributing Sources